Merck/Aetna Pact Links Januvia Value-Based Payment To Treatment Intensification
Merck will use the need for added therapies as a measure to determine rebate value – one that might be more straightforward than monitoring hemoglobin A1C data.
Merck will use the need for added therapies as a measure to determine rebate value – one that might be more straightforward than monitoring hemoglobin A1C data.